Invention Grant
- Patent Title: ADAMTS binding immunoglobulins
-
Application No.: US16617885Application Date: 2018-06-04
-
Publication No.: US11261260B2Publication Date: 2022-03-01
- Inventor: Marie-Ange Buyse , Guy Hermans , Sven Lindemann , Hans Guehring , Ralf Guenther , Roland Kellner
- Applicant: Merck Patent GmbH , ABLYNX NV
- Applicant Address: DE Darmstadt; BE Zwijnaarde
- Assignee: Merck Patent GmbH,ABLYNX NV
- Current Assignee: Merck Patent GmbH,ABLYNX NV
- Current Assignee Address: DE Darmstadt; BE Zwijnaarde
- Agent Seth E. Cockrum
- Priority: EP17174403 20170602
- International Application: PCT/EP2018/064665 WO 20180604
- International Announcement: WO2018/220234 WO 20181206
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K16/18 ; C07K16/40 ; A61K39/00 ; A61P19/02

Abstract:
The present invention relates to immunoglobulins that bind ADAMTS5 and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein. Other aspects, embodiments, advantages and applications of the invention will become clear from the further description herein.
Public/Granted literature
- US20200317802A1 ADAMTS BINDING IMMUNOGLOBULINS Public/Granted day:2020-10-08
Information query